Bhavna Verma, PhD1, Georgia Z. Chen, PhD2, Edmund K. Waller, PhD2, Neal Goodwin, PhD1, Angela Davies, PhD1, Amy Wesa, PhD1 and Nabil F. Saba, PhD2
1Champions Oncology, USA. 2Winship Cancer Institute of Emory University, USA.
Humanized mice generated by hematopoietic stem cells (HSC) transplant and co-engrafted with a patient-derived xenograft (PDX) represents a promising pre-clinical platform for studying immunological response to cancer and evaluation of immunotherapeutic interventions. These models are limited by the fact that the immune system developed in these mice is allogeneic to the tumor. To address this, we have innovated a platform to reconstitute autologous HIS in immunodeficient NOG-EXL mice with mobilized peripheral blood (MPB)-CD34 cells derived from a head and neck cancer patients along with PDX generated from the same patient tumor tissue.